Gastric Adenocarcinoma Recruiting Phase 2 Trials for Oxaliplatin (DB00526)

Back to Gastric Adenocarcinoma

Also known as: Adenocarcinoma gastric / Adenocarcinoma, Gastric / Gastric Adenocarcinomas / Adenocarcinoma of the Stomach / Stomach Adenocarcinoma / Gastric Cancer, Adenocarcinoma / Adenocarcinoma of stomach (disorder)

Indication	Status	Phase
DBCOND0030814 (Gastric Adenocarcinoma)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05836584	Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer	Treatment	Atezolizumab (DB11595) Calcium (DB01373) Capecitabine (DB01101) Docetaxel (DB01248) Fluorouracil (DB00544) Leucovorin (DB00650) Levoleucovorin (DB11596) Oxaliplatin (DB00526)
NCT05177133	Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)	Treatment	Capecitabine (DB01101) Oxaliplatin (DB00526) Retifanlimab (DB15766)
NCT06196697	AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer	Treatment	Cadonilimab (DB16680) Capecitabine (DB01101) Ivonescimab (DB18931) Oxaliplatin (DB00526) Tegafur (DB09256)
NCT06123338	A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer	Treatment	Capecitabine (DB01101) Oxaliplatin (DB00526) Pembrolizumab (DB09037) Trastuzumab (DB00072)
NCT04999332	Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer	Treatment	Docetaxel (DB01248) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT05476796	Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer	Treatment	Nivolumab (DB09035) Oxaliplatin (DB00526) Tipiracil (DB09343) Trifluridine (DB00432)
NCT05567835	A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer	Treatment	Docetaxel (DB01248) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT04150640	Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma	Treatment	Fluorouracil (DB00544) Irinotecan (DB00762) Nivolumab (DB09035) Oxaliplatin (DB00526) Pembrolizumab (DB09037) Trastuzumab (DB00072)
NCT05715931	Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma	Treatment	Docetaxel (DB01248) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526) Toripalimab (DB15043) Trastuzumab (DB00072)
NCT05872685	Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)	Treatment	Oxaliplatin (DB00526) Serplulimab (DB17451)
NCT05729646	Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma	Treatment	Oxaliplatin (DB00526) Toripalimab (DB15043)